Biomedical Engineering Reference
In-Depth Information
51. Zhou YZ, Alany RG, Chuang V, Wen J (2013)
Optimization of PLGA nanoparticles formula-
tion containing
L
-DOPA by applying the cen-
tral composite design. Drug Dev Ind Pharm 39
(2):321-330. doi:
10.3109/03639045.2012.
681054
52. ICH Q3C (R4) (2003) Guidance (Interna-
tional Conference on Harmonisation). Impu-
rities: Guideline for Residual Solvents
53. Abdelwahed W, Degobert G, Stainmesse S,
Fessi H (2006) Freeze-drying of nanoparticles:
formulation, process and storage considera-
tions.
Adv
Drug
Deliv
Rev
58
(15):1688-1713.
doi:
10.1016/j.addr.2006.
09.017
54. Luan X, Skupin M, Siepmann J, Bodmeier R
(2006) Key parameters affecting the initial
release (burst) and encapsulation efficiency of
peptide-containing poly(lactide-co-glycolide)
microparticles. Int J Pharm 324(2):168-175.
doi:
10.1016/j.ijpharm.2006.06.004